Riluzole-13C,15N2 – 1 mg

Brand:
Cayman
CAS:
1215552-03-6
Storage:
-20
UN-No:
De Minimis - 2811 / 6.1

Riluzole-13C,15N2 is intended for use as an internal standard for the quantification of riluzole (Item No. 14577) by GC- or LC-MS. Riluzole is a benzothiazole derivative with anti-excitotoxic effects that acts by blocking the presynaptic release of glutamate, indirectly antagonizing glutamate receptors, and inactivating neuronal voltage-gated Na+ channels (ED50 = 2.3 μM).{22851} Riluzole suppresses glutamate-induced seizures in rats at an ED50 value of 3.2 mg/kg and displays neuroprotective effects in hypoxic animals at an ED50 value of 4 mg/kg. Formulations containing riluzole have been explored as therapeutics for slowing disease progression of amyotrophic lateral sclerosis.  

 

Available on backorder

SKU: 25361 - 1 mg Category:

Description

An internal standard for the quantification of riluzole by GC- or LC-MS


Formal name: 6-(trifluoromethoxy)benzo[d]thiazol-2-13C-3-15N-2-amine-15N

Synonyms: 

Molecular weight: 237.2

CAS: 1215552-03-6

Purity: ≥98%

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Ion Channel Modulation|Blockers||Product Type|Biochemicals|Isotopically Labeled Standards|13C||Product Type|Biochemicals|Isotopically Labeled Standards|15N||Research Area|Neuroscience|Neurodegenerative Disorders||Research Area|Neuroscience|Seizure Disorders